4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Atherosclerosis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 642 ongoing clinical trials involving Atherosclerosis
Of the 642 trials,327 trials are in Phase III
Furthermore, 145 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Atherosclerosis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Atherosclerosis, a cardiovascular disorder. The highest number of ongoing clinical trials involving Atherosclerosis is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions involved in Atherosclerosis-related drug trials.

Novartis AG: The leading ongoing Atherosclerosis related clinical trial sponsor

Novartis AG is the top sponsor for Atherosclerosis-related ongoing clinical trials.

Meril Life Sciences Pvt Ltd, Concept Medical Inc, Amgen Inc, and Novo Nordisk AS are a few other notable clinical trial sponsors involving Atherosclerosis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Atherosclerosis

Rosuvastatin calcium (Crestor, Crestastatin, Provisacor and Visacor), Clopidogrel bisulfate (Plavix, Iscover, Sanik, Lopigrel, Clopidogrel), and Evolocumab (AMG-145, Repatha) are among the key marketed drugs involving Atherosclerosis.

Rosuvastatin calcium (Crestor, Crestastatin, Provisacor and Visacor) is an antilipemic agent, belongs to cardiovascular system class. Rosuvastatin calcium functions via 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase (HMG CoA Reductase or Hydroxymethylglutaryl CoA Reductase or HMGCR or EC 1.1.1.34) Inhibitor mechanism of action. It is formulated as tablets, film coated tablets for oral route of administration. It is marketed for the treatment of Atherosclerosis and several other indications including Cardiovascular Risk Factors, Myocardial Infarction, Hypercholesterolemia, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Congestive Heart Failure (Heart Failure), Stroke, Homozygous Familial Hypercholesterolemia (HoFH), Dyslipidemia, Hyperlipidemia. Rosuvastatin calcium was first approved in 2002 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by AstraZeneca plc and several other companies including Abbott Laboratories, Grunenthal GmbH, and A.Menarini New Zealand Pty Ltd.

Clopidogrel bisulfate (Plavix, Iscover, Sanik, Lopigrel, Clopidogrel) is a thienopyridine antiplatelet agent. Clopidogrel bisulfate functions via P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y(cyc) or P2Y12 or P2RY12) Antagonist mechanism of action.  It is formulated as tablets, coated tablets and film coated tablets for oral route of administration. It is marketed for the treatment of Atherosclerosis and several other indications including Angina (Angina Pectoris), Thrombosis, Myocardial Infarction, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Stroke, Unstable Angina, Ischemic Stroke, Atrial Fibrillation, Acute Coronary Syndrome, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Ischemia. Clopidogrel bisulfate was first approved in 1997 and is marketed globally including the US, the UK, Australia, France, Germany, China and Japan by Sanofi and several other companies including Medley Industria Farmaceutica Ltda, and Bristol-Myers Squibb Co.